Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation.

Blood
Chen-Hua YanXiao-Jun Huang

Abstract

We studied the impact of risk stratification-directed interventions for minimal residual disease (MRD) on relapse and disease-free survival (DFS) prospectively in 814 subjects with standard-risk acute leukemia receiving allotransplantation in first or second complete remission. A total of 709 subjects were MRD(-) after transplantation (Group A); 105 subjects were MRD(+), 49 received low-dose IL-2 (Group B), and 56 received modified donor lymphocyte infusion (DLI) with or without low-dose IL-2 (Group C). Posttransplantation immune suppression for GVHD was also modified based on MRD state. The cumulative risk of relapse was significantly less and DFS was significantly better in subjects in Group C than in subjects in Group B (P = .001 and P = .002, respectively), but was not different from subjects in Group A (P = .269 and P = .688, respectively). Multivariate analyses confirmed that MRD state and modified DLI were significantly correlated with relapse (P = .000, odds ratio [OR] = 0.255 and P = .000, OR = 0.269) and DFS (P = .001, OR = 0.511 and P = .006, OR = 0.436, respectively). These data suggest that risk stratification-directed interventions with modified DLI in patients with standard-risk acute leukemia who are MRD(+) afte...Continue Reading

References

Apr 24, 1975·The New England Journal of Medicine·E D ThomasC D Buckner
Jan 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J MortimerE D Thomas
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R H CollinsJ Nemunaitis
Oct 15, 2005·The Journal of Clinical Investigation·Edward S MorrisGeoffrey R Hill
Apr 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hélène LapillonneJudith Landman-Parker
Jan 16, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Martha L ArellanoEdmund K Waller
Nov 15, 2007·Cancer·Wolfgang KernSusanne Schnittger
Dec 20, 2008·American Journal of Clinical Pathology·Adhra Al-MawaliIan Lewis
Mar 13, 2009·Haematologica·Nicolaus KrögerUNKNOWN Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transpl
Jan 12, 2010·Bone Marrow Transplantation·L ScruccaF Aversa

❮ Previous
Next ❯

Citations

Jun 27, 2013·Nature Reviews. Clinical Oncology·Christopher S Hourigan, Judith E Karp
Dec 18, 2012·Cancer Cell International·Yangqiu LiChristian A Schmidt
Mar 20, 2012·Journal of Hematology & Oncology·Meng Lv, Xiao-Jun Huang
Mar 29, 2014·Annals of Hematology·Maximilian ChristopeitUlrike Bacher
Dec 5, 2013·International Journal of Hematologic Oncology·Lindsay Am ReinDavid A Rizzieri
Mar 24, 2016·Seminars in Hematology·Ying-Jun Chang, Xiao-Jun Huang
Jun 28, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Xiao-Dong MoXiao-Jun Huang
Jun 21, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J LiuX J Huang
Feb 5, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sophie HaroVirginie Gandemer
May 6, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yuan KongXiao-Jun Huang
Feb 4, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christopher S HouriganMarcos de Lima
Jul 25, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yuan KongXiao-Jun Huang
Oct 16, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yu WangXiao-Jun Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.